Cushing's syndrome is a hypercortisolism disorder caused by prolonged exposure to excessive cortisol or cortisol-like medications. It may arise from exogenous glucocorticoid use or endogenous causes such as ACTH-dependent and ACTH-independent conditions. Clinical impact can be substantial and diagnosis is often challenging.
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
A securities class action alleges Corcept misled investors about the regulatory prospects for relacorilant. The suit cites an FDA Complete Response Letter, a 50.4% stock drop, and an April 21, 2026 lead plaintiff deadline.
Corcept Therapeutics executives and directors were sued over alleged misstatements about a drug candidate’s approval prospects. The suit says insider stock sales totaled $97 million while the stock price was artificially inflated.
Italian pharmaceutical company Recordati reported 2025 revenues of €2.6 billion and adjusted net profit of €651.1 million, with rare disease therapies driving 29.7% growth. The company projects 2026 core earnings of €995 million to €1.03 billion, anticipating continued momentum in its specialized rare disease treatments.
Belite Bio announced preliminary Q4 2025 results and plans to submit an NDA for tinlarebant in Q2 2026 following positive Phase 3 trial results. BioArctic reported record financial results with operating profit exceeding SEK 1.2 billion for 2025. Recordati delivered strong preliminary full-year 2025 results despite FX headwinds.
Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.
The U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals did not infringe Corcept Therapeutics' patents for methods of safely co-administering Korlym with CYP3A4 inhibitors, affirming a 2023 district court verdict.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07282223 |
Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism |
COMPLETED | |
| NCT05633953 |
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome |
COMPLETED | |
| NCT03817840 |
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease |
COMPLETED | |
| NCT03606408 |
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 |
COMPLETED | PHASE2 |
| NCT02922257 |
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery |
COMPLETED | |
| NCT02889224 |
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man |
COMPLETED | NA |
| NCT02804750 |
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome |
COMPLETED | PHASE2 |
| NCT02663609 |
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome |
COMPLETED | |
| NCT02468193 |
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome |
COMPLETED | PHASE2 |
| NCT02297945 |
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome |
COMPLETED | PHASE3 |
